IQVIA (IQV) Stock Forecast & Price Target

$208.13 +0.28 (+0.13%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$205.92 -2.21 (-1.06%)

As of 04:06 AM Eastern

Compare

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
3

Buy
14

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 3 have given a hold rating, and 14 have given a buy rating for IQV.

Consensus Price Target

$224.82
8.02% Upside

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $224.82. The highest price target for IQV is $255.00, while the lowest price target for IQV is $185.00. The average price target represents a forecasted upside of 8.02% from the current price of $208.13.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

Type	Current Forecast 7/13/25 to 7/13/26	1 Month Ago 6/13/25 to 6/13/26	3 Months Ago 4/14/25 to 4/14/26	1 Year Ago 7/13/24 to 7/13/25
Strong Buy	0 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	16 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$224.82	$224.13	$226.63	$219.90
Forecasted Upside	8.02% Upside	23.76% Upside	29.25% Upside	35.13% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	Broader Market
Consensus Rating Score	2.82	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	8.02% Upside	701.52% Upside	13.82% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/9/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Set Target		$240.00	+14.43%
7/6/2026	HSBC 3 of 5 stars		Reiterated Rating	Buy	$240.00	+16.25%
7/1/2026	Robert W. Baird 3 of 5 stars	Eric Coldwell 2 of 5 stars	Boost Target	Outperform	$230.00 ➝ $249.00	+28.66%
6/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kallum Titchmarsh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$225.00 ➝ $200.00	+11.71%
5/4/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C) ➝ Hold (C-)
4/8/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$185.00	+10.93%
3/9/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$174.00 ➝ $213.00	+22.02%
3/6/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$210.00	+17.65%
3/3/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Halsted Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$221.00	+26.66%
2/23/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$215.00	+32.20%
Trump's gold order: the announcement they won't put on the front page (Ad) On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. Request the free guide in 30 seconds and get positioned now
2/19/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$290.00 ➝ $245.00	+48.73%
2/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$280.00 ➝ $240.00	+30.09%
2/6/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean Dodge Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$250.00	+34.06%
2/6/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$273.00 ➝ $220.00	+19.25%
2/6/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$255.00 ➝ $225.00	+20.00%
2/6/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$270.00 ➝ $255.00	+36.01%
2/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$230.00 ➝ $200.00	+6.68%
9/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$214.00	+17.92%
7/23/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/20/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Garro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$255.00 ➝ $235.00	+17.54%
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$280.00 ➝ $250.00	+20.00%
7/31/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:29 AM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 9, 2026. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

The company recently reported earnings per share of $2.90, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
IQVIA Holdings Inc. has experienced an 8.4% increase in revenue compared to the same quarter last year, showcasing its ability to grow in a competitive market.
The stock is currently trading at approximately $177, which may be seen as undervalued, especially with the board's recent approval of a $2.00 billion share buyback program, indicating confidence in the company's future.
Analysts predict an earnings per share of 11.6 for the current year, suggesting a positive outlook for the company's profitability.
IQVIA Holdings Inc. operates in the growing life sciences sector, providing advanced analytics and technology solutions, which positions it well for future demand in drug development and healthcare analytics.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

The company's debt-to-equity ratio is relatively high at 2.20, which may indicate higher financial risk and potential challenges in managing debt levels.
Despite recent revenue growth, the stock has seen fluctuations, with a twelve-month high of $247.04 and a low of $154.50, suggesting volatility that could deter risk-averse investors.
Analyst ratings are mixed, with some downgrading the stock from "buy" to "hold," which may reflect uncertainty about future performance.
The quick and current ratios are both at 0.75, indicating potential liquidity issues that could affect the company's ability to meet short-term obligations.
Market conditions and competition in the life sciences sector could pose challenges, impacting IQVIA Holdings Inc.'s growth and profitability in the future.

IQV Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $224.82, with a high forecast of $255.00 and a low forecast of $185.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 8.02% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 1 downgrade by analysts.

IQVIA has been rated by research analysts at Deutsche Bank Aktiengesellschaft, HSBC, Morgan Stanley, Robert W. Baird, and Weiss Ratings in the past 90 days.

Analysts like IQVIA more than other "medical" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IQVIA Recommendations

This page (NYSE:IQV) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

IQV Analyst Ratings Over Time

IQV Analyst Recommendations By Month

IQV Price Targets by Month

IQVIA Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

IQVIA
Bull Case

IQVIA
Bear Case

IQV Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IQVIA Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IQVIA (IQV) Stock Forecast & Price Target

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

IQV Analyst Ratings Over Time

IQV Analyst Recommendations By Month

IQV Price Targets by Month

IQVIA Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

IQVIA Bull Case

IQVIA Bear Case

IQV Forecast - Frequently Asked Questions

What is IQVIA's forecast for 2026?

Should I buy or sell IQVIA stock right now?

Does IQVIA's stock price have much upside?

Has IQVIA been downgraded by Wall Street analysts recently?

What analysts cover IQVIA?

Do Wall Street analysts like IQVIA more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IQVIA Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

IQVIA
Bull Case

IQVIA
Bear Case